Fanconi anaemia (FA) is an accepted indication for treatment with allogeneic HLA-identical BMT. Most patients, however, lack a suitable HLA-identical donor. In our centre, six FA patients were transplanted with a matched unrelated donor. Due to hypersensitivity to DNA cross-linking agents, a low-dose cyclophosphamide (CY) and thoraco-abdominal irradiation (TAI) regimen is recommended for conditioning in FA. We added Ara-C upfront and anti-T cell antibodies to enhance engraftment and to prevent GVHD, in combination with T cell depletion in four out of six of the first transplants. One patient did not engraft. In three patients rejection was observed. In three of these four patients a second BMT, using full bone marrow grafts, resulted in successful engraftment. The other patient died before a second BMT could be performed. The incidence and severity of acute GVHD was low: only one patient with grade III acute GVHD was seen. Two out of four surviving patients suffered from chronic GVHD. Four patients survived (median survival time 43 months after BMT), three with good and one with acceptable quality of life. Two patients died, one patient due to adenoviral reactivation with multi-organ failure, and one due to sepsis complicated by ARDS. In conclusion, MUD BMT is feasible in FA patients with bone marrow failure in whom no HLA-identical sibling donor is available. In our study group, the major problem was graft rejection, despite the administration of a combination of graft enhancing anti-T cell antibodies. Multicentre studies are needed to determine a more intensive, but still tolerable, conditioning regimen. Keywords: Fanconi anaemia; unrelated bone marrow transplantation; aplastic anaemia; graft-versus-host disease; anti-T cell antibodies Fanconi anaemia (FA) is an autosomal recessive disorder, usually characterized by several congenital malformations, progressive bone marrow failure and an increased incidence of malignancies. Cells from FA patients are hypersensitive Current treatment of FA patients consists of supportive care, ie blood transfusions, anabolic steroids or haematopoietic growth factors, all having their limitations and sideeffects. To treat the haematological disorder, BMT with an HLA-identical sibling donor is now performed in many patients. 3 The 2-year probability of survival after HLAidentical BMT in 151 FA patients registered by the International Bone Marrow Transplant Registry was found to be 66% (95% confidence interval: 58% to 73%), 3 including five of our patients of whom four are alive. Based on the in vitro sensitivity of FA cells, a conditioning regimen was recommended using low-dose (20 mg/kg) cyclophosphamide (CY) and 5 Gy thoraco-abdominal irradiation (TAI).
to DNA crosslinking agents, which is used as a diagnostic tool. 1 Complementation studies have shown at least five genetic subtypes in FA patients. 2 Current treatment of FA patients consists of supportive care, ie blood transfusions, anabolic steroids or haematopoietic growth factors, all having their limitations and sideeffects. To treat the haematological disorder, BMT with an HLA-identical sibling donor is now performed in many patients. 3 The 2-year probability of survival after HLAidentical BMT in 151 FA patients registered by the International Bone Marrow Transplant Registry was found to be 66% (95% confidence interval: 58% to 73%), 3 including five of our patients of whom four are alive. Based on the in vitro sensitivity of FA cells, a conditioning regimen was recommended using low-dose (20 mg/kg) cyclophosphamide (CY) and 5 Gy thoraco-abdominal irradiation (TAI). 4 Most patients, however, lack a suitable matched sibling donor, and for increasing numbers of patients a matched unrelated donor (MUD) is sought. Data regarding MUD BMT for FA are still limited. Major complications include non-engraftment, graft rejection and severe GVHD. Survival rate and quality of life after matched unrelated BMT are poor.
We describe the results of six FA patients with aplastic anaemia, whom we decided to transplant with a MUD bone marrow graft. We used a low-dose CY and TAI conditioning regimen, to which we added Ara-C and anti-T cell antibodies to enhance engraftment.
Patients and methods

Patients
Between 1992 and 1995, six patients with FA received a total of nine BMTs from eight MUDs and one haplo-identical sibling donor. In all patients the diagnosis of FA was confirmed with mitomycin-C induced chromosomal breakage analysis. 1 Pretransplant patient characteristics are shown in Table  1 . Age at transplant varied from 4 to 19 years. Three patients suffered from moderate aplastic anaemia (MAA) and three from severe aplastic anaemia (SAA) according to Camitta's criteria. 5 No patients were diagnosed with very severe aplastic anaemia (VSAA), myelodysplastic syndrome or leukaemia. Prior treatment consisted of erythro- cyte and platelet transfusions. In one patient androgen therapy was given, but discontinued when he developed hepatocellular carcinoma. The carcinoma was resected without recurrence to date. Chromosomal analysis showed normal karyotypes in all patients; no clonal chromosomal abnormalities were detected. In three patients complementation group analysis was performed (by H Joenje, Department of Human Genetics, Free University, Amsterdam): two patients belonged to group C and the other to group E. 6 
Donor selection
Donor searches were performed by Europdonor Foundation, Leiden University Hospital. Using the 'Bone Marrow Donors Worldwide' file, donors were located. HLA-A, B, DR identical donors were selected and retyped using the standard NIH lymphocytotoxicity assay for the HLA-A, -B and -C antigens, and the two-colour fluorescence assay for HLA-DR and -DQ. DNA typing for the HLA-A2 and -DQB1 subtypes was performed using the PCR sequence specific primer (PCR-SSP) technique and HLA-C, -DRB1 and -DPB1 by PCR sequence specific oligonucleotide probe (PCR-SSOP).
Details of donor age and sex, as well as HLA-matching are shown in Table 2 .
To determine the risk for rejection and GVHD, in almost all cases mixed lymphocyte culture (MLC, in both GVH and HVG direction) and cytotoxic T lymphocyte precursor frequency (CTLp, in GVH direction only) testing was done. MLC and CTLp frequency were considered negative if the relative response value was р10% and the frequency р1:10 6 , respectively. Results are shown in Table 2 . Three patient-donor combinations showed no mismatches; the other three showed mismatches but CTLp testing was negative.
Transplant procedure
Details of the transplant procedure are shown in Table 3 .
All patients received conditioning with CY (10 mg/kg i.v. for 4 days; days Ϫ5 to Ϫ2) and Ara-C (2 g/m 2 i.v. for 2 days; days Ϫ8 and Ϫ7), as well as single-dose TAI (400-500 cGy) at day Ϫ1. At first transplant four patients received TCD marrow by albumin-gradient centrifugation followed by E-rosette sedimentation; 7 two patients received full bone marrow. Full bone marrow grafts were used also for second BMTs. Anti-T cell antibodies, either rabbit antithymocyte globulin (ATG) (2 mg/kg/day i.v. for 2 days; days Ϫ6 and Ϫ5) or Campath-1G (anti-CD52) (0.2 mg/kg/day i.v. for 3 days; days Ϫ6 to Ϫ4), were used before BMT to enhance engraftment. Anti-lymphocyte function associated antigen-1 (anti-LFA-1) (0.2 mg/kg i.v. for 14 days; days Ϫ3 to +10) and anti-CD2 (0.2 mg/kg i.v. for 14 days; days Ϫ2 to +11) were added where TCD of the graft had been carried out. 8 If full bone marrow was infused we gave Campath-1G 'over the graft' (0.2 mg/kg i.v. for 11 days; days Ϫ5 to +5) to enhance engraftment and to reduce GVHD (according to protocol 6 by Hale and Waldmann). 9 In patient 5, at second BMT rabbit ATG was prescribed for conditioning, but had to be discontinued due to anaphylaxis. To complete conditioning Campath-1G was used instead of ATG.
The number of nucleated marrow cells counted before TCD varied between 1.4 and 19.2 × 10 8 /kg. Post-BMT GVHD prophylaxis was MTX-CsA based, as shown in Table 3 . 3, 10 MTX was given at a dose of 10 mg/m 2 i.v. on days +1, +3 and +6. CsA was given at a dose of 2 mg/kg/day i.v., or 6 mg/kg/day orally, continued for 6 months, after which the drug was tapered and finally stopped. ND = not done; U = unknown; MLC = mixed lymphocyte culture; CTLp = cytotoxic T lymphocyte precursor frequency; % RR = relative response value. a HLA haplo-identical sibling transplantation. CsA TAI 500 cGy Steroids CY = cyclophosphamide; MTX = methotrexate; Bus = busulfan; CsA = cyclosporin A; Ara-C = cytosine arabinoside; TAI = thoraco-abdominal irradiation; ATG = anti-thymocyte globulin.
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Supportive care
All patients were treated in strict reversed isolation in down-flow laminar air facilities and received total bowel decontamination by non-absorbable antimicrobials.
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Before discharge, patients received bowel re-contamination. CMV-seronegative patients received CMV-seronegative blood products. All blood products were leucocytedepleted and irradiated.
Engraftment
Chimerism pattern analysis, using FACS separated white blood cell subpopulations, was performed with different techniques: fluorescent in situ hybridization with a Y-chromosome-specific probe (Y-FISH), 12 chromosomal polymorphism testing by PCR of VNTR or CA-repeats 13 and/or chromosome banding techniques.
Results
Engraftment
At first transplant five out of six patients engrafted. Patient 5 did not engraft. She developed a febrile transfusion reaction during the infusion of the non-TCD graft. No haematological recovery occurred. Before and after BMT crossmatching studies using the patient's serum against donor lymphocytes were negative, but after BMT we found positive cross-matching studies with donor granulocytes. A humoral immune response may have caused the reaction observed. A second matched unrelated non-TCD BMT was performed within 1 month of the first BMT. She then engrafted without problems and showed complete chimerism.
In three out of five patients, rejection was observed after initial engraftment. In patient 3, mixed chimerism (Y-FISH) was observed 6 weeks post-BMT with 61% cells of donor origin. After 9 months haematopoiesis was insufficient with domination of host-type cells (60%, Y-FISH) and a second BMT, using a haplo-identical sibling donor graft, was performed, 10 months after the first BMT. This resulted in successful engraftment. Patient 4, transplanted with a TCD graft, showed rejection after an initial rise in PMN (day +12 post-BMT: 0.066 × 10 9 /l) and the appearance of reticulocytes on the same day. At day +13 a sudden decline in cell numbers was observed. Treatment for rejection was unsuccessful. The second matched, unrelated non-TCD BMT was performed 2 months after the first transplant. Appropriate haematological recovery was observed (PMN Ͼ0.1 × 10 9 at day +20, and reticulocytosis). However, on day +43 a sudden decline in leucocyte count occurred, which was promptly treated with steroids, Campath-1G and G-CSF, finally resulting in successful engraftment with complete chimerism. Patient 6, transplanted with a non-TCD graft, rejected at day +30, after an initial take (at day +27 Y-FISH showed 98% donor-type cells). Treatment for rejection with Campath-1G, methylprednisolone and G-CSF was unsuccessful. The patient died at day +49 from complications (sepsis, ARDS, gastrointestinal bleeding) before a second BMT could be performed.
The two other engrafted patients (Nos 1 and 2) showed complete chimerism.
In conclusion, we performed eight MUD and one haploidentical sibling donor transplants in six patients and eventually achieved engraftment in all patients, although in three patients a second BMT had to be performed because of one non-engraftment and two rejections.
Graft-versus-host disease
All patients were evaluable for acute GVHD, although one patient died at day +49 post-BMT. Two patients (Nos 1 and 3) did not develop any sign of acute GVHD. Patients 2 and 6 developed acute GVHD grade I involving the skin, treated successfully with steroids. Patient 4 suffered from acute GVHD grade II involving the skin and patient 5 showed acute GVHD grade III, with involvement of the skin, lungs, liver and gastro-intestinal tract, treated with CsA and steroids.
Four patients were evaluable for chronic GVHD. Patients 1 and 2 showed no signs of chronic GVHD. Patient 4 developed limited chronic GVHD of the skin treated with steroids. Eighteen months after BMT he developed autoimmune haemolytic anaemia and thrombocytopenia probably related to chronic GVHD. Patient 5 suffers from extensive chronic GVHD, the main problem being bronchiolitis obliterans (although not histologically proven by lung biopsy). She was treated with immunosuppression (steroids and CsA). Her condition is now slightly improving.
Other complications
In two patients haemorrhagic cystitis occurred, probably related to CY, despite the use of mesna prophylaxis. In patient 4, hypertension and moderate chronic renal insufficiency (creatinine 100-150 mol/l) was diagnosed. Ultrasound examination showed two small kidneys (left kidney 6 cm and right kidney only 3 cm). Kidney biopsy showed interstitial fibrosis and tubular necrosis, probably due to the toxicity of pre-treatment. Dialysis has not been needed to date. Oropharyngeal mucositis was present in all patients; in three, herpes simplex infection was suspected and confirmed in two of them; all three were treated with acyclovir. In five patients positive blood cultures were obtained; all bacteriaemies were successfully treated with antibiotics. One patient was treated with foscarnet for CMV reactivation. No fungal infections were diagnosed. Patient 3 died at day +100 after the second (haplo-identical sibling donor) BMT due to adenovirus reactivation with encephalitis and hepatic necrosis, proven at autopsy. At that time the bone marrow was hypocellular but of donor origin. A boost with marrow from the same donor was planned, but the patient died before infusion was effected. Patient 6 became septic 12 days after BMT; blood cultures were positive for Streptococcus mitis and Staphylococcus epidermidis. She required treatment for septic shock and ARDS and was mechanically ventilated for 10 days. Complete chimerism was diagnosed, but 30 days post-BMT rejection was observed and treatment was unsuccessful. A second sepsis (Staphylococcus epidermidis) occurred with severe gastrointestinal haemorrhage. Again she developed respiratory insufficiency, and died at day +49 post-BMT.
Outcome
Four out of six patients are surviving with a median survival time of 43 months after BMT (updated 1 June 1997). Two patients (Nos 1 and 2) are well and completely haematologically recovered, at 60 and 51 months after BMT, respectively. Patient 4 suffers from moderate chronic renal insufficiency (creatinine 130 mol/l). One year ago he was treated for auto-immune haemolytic anaemia and thrombocytopenia with steroids, CsA and immunoglobulins. Now, 35 months after BMT, he is in a stable condition with tapering of steroids. Patient 5, now 32 months after BMT, suffers from bronchiolitis obliterans and is treated with low-dose steroids and CsA. Her general well-being has improved slightly over the last 10 months.
Karnofsky scores of surviving children are given in Table 4 .
Discussion
It is generally known that not all patients diagnosed with FA present with severe haematological disease.
14 Recently, data were presented on the disease progression of 388 FA patients enrolled in the IFAR, of whom 328 showed the characteristic congenital and/or haematological abnormalities, and of whom 60 were siblings of probands. By 40 years of age these 388 patients carry an actuarial risk of 98% for cytopenia and 52% for either MDS or AML. 15 Treatment for haematological disease in FA patients can be either supportive, ie blood transfusions, anabolic steroids or haematopoietic growth factors, or curative by BMT. Clear cut criteria concerning the timing of BMT in FA patients do not exist. So far, mainly BMT with HLA-identical sibling donors have been performed, with acceptable toxicity and cure rates of 47-94%. 3, [16] [17] [18] [19] HLA-identical sibling donors, however, are only available to a minority of the patients. To overcome this problem MUD grafts can be used.
Our patients were all suffering from pancytopenia with trilineage involvement on bone marrow aspirate. Because of their young age, treatment with androgens was considered undesirable, due to the side-effects of this treatment. The one patient who was treated with androgens developed hepatic carcinoma, which was resected without recurrence. Also, we felt that further conservative treatment would only postpone curative therapy attempts, and therefore might lead to the development of MDS or AML, infectious complications or to allosensitization due to multiple transfusions. The absence of these complications in our patient group certainly contributed to the favourable survival rate.
For all patients an optimally matched unrelated donor was available. In four out of five tested cases the CTLp frequency was negative, and in one only slightly positive (1:10 6 ). The CTLp frequency is known to predict for risk Died day +100, multi-organ failure due to adenovirus reactivation (hepatic necrosis and encephalitis) -4
Alive 35 months after transplant 80% Mild controlled GVHD skin, renal insufficiency (no dialysis needed so far). Delayed immunologic reconstitution, auto-immune haemolytic anaemia and thrombocytopenia 5
Alive 32 months after transplant 60% Acute GVHD gut and chronic GVHD, ie bronchiolitis obliterans 6 Died day +49, sepsis complicated by ARDS and gastro-intestinal bleeding -of acute GVHD III-IV, transplant-related mortality and patient survival. 20, 21 Our conditioning regimen was based on the low-dose CY and TAI regimen, as recommended before. 4 Initially, we added Ara-C (2 g/m 2 i.v. for 2 days) as we hypothesized that more aggressive pretransplant immune suppression was needed in unrelated BMT, to reduce graft rejection. Ara-C was chosen because it is a non-alkylating drug. Also, it is used successfully for conditioning of patients with severe aplastic anaemia grafted with an unrelated donor. 22 Augmenting the cyclophosphamide dose was considered undesirable, because severe toxicity has been observed with conditioning regimens containing higher doses of cyclophosphamide in FA patients. 23 In this context, it is remarkable that three of our patients who received a second BMT in fact tolerated the second conditioning regimen without major toxicities.
In cases of TCD, immunosuppressive antibodies (anti-LFA-1, anti-CD2, Campath-1G or ATG) were added to enhance engraftment. If a full bone marrow graft was used Campath-1G was administered 'over the graft' (according to protocol 6 by Hale and Waldmann), 9 both to enhance engraftment and to reduce the incidence and severity of acute GVHD.
Only a few papers address MUD BMT in FA patients, and most reports reveal few details. Recently, Gluckman et al 3 reported a multi-centre study from the International Bone Marrow Transplant Registry, presenting data on 151 HLA-identical sibling transplants with a 2-year probability of survival of 66%, and on 48 alternative donor transplants (among which 19 MUD transplants) showing a 2-year probability of survival of 29%. Published results from singlecentre experiences on unrelated BMT in FA are scarce. Souillet et al 24 reported two patients who did not engraft. Gluckman et al 16 reported 10 patients, of whom four survived. Hows et al 17 described four patients, using TCD grafts in three out of four. One patient survived with chronic GVHD. Three patients died, two with graft failure, one with sepsis and acute GVHD grade III. A first report on the successful use of peripheral blood stem cells from an unrelated donor to transplant a FA patient was recently published. 25 Davies et al 26 published a paper on seven MUD BMTs in FA patients. A striking difference between Davies' and our patient group was the disease status of the patients. In Davies' group, most patients had clonal chromosomal abnormalities or had already progressed to MDS/AML (n = 5). In our group, only patients with aplastic anaemia were transplanted. Also, conditioning regimens and the composition of the graft were different. We used TCD grafts in four out of six first transplants, whereas Davies used full bone marrow grafts. Engraftment results were similar, but our results were hampered by rejections, probably due to T cell depletion. In Davies' series only one patient rejected after initial engraftment and received a successful second marrow infusion from the same donor. We observed three rejections and one non-engraftment. Three of these patients received a second BMT. All second transplants finally engrafted.
The incidence and severity of acute GVHD in Davies' patients was much higher than in our patients. Davies reports two patients with grade IV acute GVHD, both of whom died; two other patients suffer from extensive chronic GVHD. We only observed one patient with grade III acute GVHD and two out of four surviving patients suffer from chronic GVHD. The two surviving patients without GVHD both received TCD marrow grafts. The successful prevention of acute GVHD may be due to either TCD of the graft, the use of Campath-1G 'over the graft' or successful total gut decontamination.
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Control of GVHD is important, not only to preserve good quality of life, but also to prevent the development of solid tumours, described in FA patients after BMT. 27 In conclusion, our data show that MUD transplantation in FA is possible with outcomes varying from excellent quality of life to chronic morbidity from GVHD or death. No definite conclusions can be drawn from this small number of patients. In view of the high risk of acute and chronic GVHD we still favour a TCD graft, preceded by an anti-T cell antibody or ATG, and followed by the combination of anti-LFA-1 plus anti-CD2 for enhancing engraftment. 8, 28 This, however, might result in a higher incidence of rejection, making a second BMT with a full bone marrow graft necessary. Therefore, multi-centre studies are needed to investigate the limits of a more intensive chemoradiotherapy before BMT, attempting to avoid rejection and re-transplantation.
If an HLA-identical sibling is available for a FA patient with bone marrow failure the decision to transplant is no longer difficult. If not, choosing the right treatment at the right moment is still problematic.
